Abstract:Background: Proton-pump inhibitors (PPIs) such as lansoprazole are the first choice treatment for EE, but they provide treatment outcomes that are not always adequate.Vonoprazan (TAK-438) belongs to the novel class of potassium-competitive acid blockers, which, unlike PPIs, reversibly inhibit the enzyme H + , K + -ATPase independently of acid pH.The aim of this phase 3, double-blind, multi-center study was to establish the non-inferior efficacy of vonoprazan 20 mg versus (vs) lansoprazole 30 mg in healing EE in non-Japanese Asian patients (pts).Methods: Pts were aged $18 years with endoscopically-confirmed EE (Los Angeles [LA] classification grade A-D); proportion of pts with LA classification grade C or D EE was planned to be $30%.Pts were stratified by baseline LA classification grade A/B vs C/D.Following a 28-day screening phase, pts were randomized 1:1 to receive vonoprazan 20 mg or lansoprazole 30 mg once daily for up to 8 weeks (wks).The primary endpoint was the EE endoscopic healing rate during 8 wks of treatment.The secondary efficacy endpoints were EE endoscopic healing rates during 2 and 4 wks of treatment.Assuming an 8-wk healing rate of 94.7% in both treatment arms, it was estimated that 240 pts per group would provide >90% power to establish non-inferiority with a 10% margin using a two-sided 95% confidence interval (CI).Safety endpoints included treatment-emergent adverse events (TEAEs).Results: A total of 244 pts received vonoprazan treatment and 237 received lansoprazole treatment.Baseline characteristics were comparable in the two treatment arms (Table 1).The 8-wk EE healing rate was 92.4% with vonoprazan and 91.3% with lansoprazole (difference [95% CI], 1.1% [-3.822%, 6.087%]); the non-inferiority of vonoprazan vs lansoprazole was therefore demonstrated.The 2-wk EE healing rate with vonoprazan (75.0%) was higher than that observed with lansoprazole (67.8%), but the difference was not statistically significant (difference [95% CI], 7.2% [-1.054%, 15.371%]).The 4-wk EE healing rate with vonoprazan (85.3%) was similar to that with lansoprazole (83.5%) (difference [95% CI], 1.8% [-4.763%, 8.395%]).In pts with baseline LA classification grade C/D, 2-, 4-, and 8-wk EE healing rates were slightly higher with vonoprazan vs lansoprazole (62.2% vs 51.5%, difference [95% CI], 10.6% [-5.708, 27.002]; 73.3% vs 67.2%, difference [95% CI], 6.2% [-8.884, 21.223]; and 84.0%vs 80.6%, difference [95% CI] 3.4% [-9.187%, 15.993%], respectively).TEAE rates were similar in the two arms: 38.1% in the vonoprazan arm vs 36.6% in the lansoprazole arm.Conclusions: Our findings demonstrate the non-inferior efficacy of vonoprazan vs lansoprazole in achieving EE healing at Wk 8 in non-Japanese Asian patients.Safety outcomes were similar in the two treatment arms.Table 1: Patient demographics and baseline characteristics (randomized set) aAt the date of informed consent.bOne patient with unknown status in the vonoprazan

A systematic review and meta‐analysis of the efficacy of vonoprazan for proton pump inhibitor‐resistant gastroesophageal reflux disease

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.

Vonoprazan versus proton‐pump inhibitors for healing gastroesophageal reflux disease: A systematic review

Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta‐analysis of randomized controlled trials

Efficacy and Safety of Vonoprazan-based Treatment of Helicobacter Pylori Infection: a Systematic Review and Network Meta-Analysis

Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prevention of Gastric and/or Duodenal Ulcers: A Systematic Review with Meta-Analysis

Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease

Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis

Vonoprazan: A systematic review of an alternative to proton pump inhibitors

Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults

Vonoprazan as a Long-Term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-Label Study

Efficacy and safety of vonoprazan versus proton pump inhibitors in the treatment of peptic ulcer disease: a systematic review and network meta-analysis for randomized controlled trails

A Comprehensive Review on the Efficacy and Safety of Vonoprazan in the Management of Gastric Acid-Related Diseases

The Role of Vonoprazan in Patients with Erosive Esophagitis.

Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

Efficacy of Long-Term Maintenance Therapy with 10-Mg Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis

Sa1089 - A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan (20 Mg Once Daily) Compared to Lansoprazole (30 Mg Once-Daily) in Patients with Erosive Esophagitis (Ee)

Long-term efficacy of on-demand vonoprazan treatment for mild reflux esophagitis: success rates and predictors of treatment failure

Network Meta-Analysis of Multiple Doses of Vonoprazan for the Treatment of Erosive Esophagitis

A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study

The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis